•  
  •  
 

Article Type

Original Study

Abstract

Objective To detect the expression of the PASD1 gene in acute myeloid leukemia (AML) patients and its relation to clinical features and complete remission of AML. Background AML is a heterogeneous disease with variable clinical outcomes. PASD1 [Per ARNT Sim (PAS) Domain containing protein 1] can stimulate autologous T-cell responses, and it is therefore considered to be a potential immunotherapeutic target for the treatment of various malignancies, including AML. Materials and methods The study was carried out on 60 AML patients (group I) and 30 healthy controls (group II). Reverse transcriptase PCR analysis of the PASD1 gene was carried out for all patients and controls. Results PASD1 was expressed in 12 (20%) AML patients, but was not expressed in any of the 30 controls. PASD1 expression was associated more with patients below 45 years (66.7% of the PASD1-positive patients were <45 years old compared with 29.2% of the PASD1-negative patients). No significant correlation was found between PASD1 gene positivity and any of the clinical and hematological variables of AML, except for less incidence of fever at presentation. PASD1-positive patients achieved more complete remission (66.7%) compared with PASD1-negative patients (35.4%) (P<0.05). Conclusion PASD1 is an attractive leukemia-associated antigen. Its expression was associated with young age and favorable outcome. However, further studies are required, with standardization of the age, clinical, and cytogenetic and molecular genetic prognostic markers, to confirm the prognostic value of PASD1 gene expression in AML, to assess its correlation with clinical features of AML patients, and to investigate its role in minimal residual disease detection and immunotherapy of AML.

Download

Share

COinS